-
Wanchun Pharmaceutical's new drug Pranabrin submitted a marketing application to the FDA and NMPA
Time of Update: 2021-04-19
A number of studies have shown that Pranabrin can prevent severe CIN caused by multiple chemotherapeutic drugs with different anti-tumor mechanisms.
-
Nearly half of the products are exempt from clinical evaluation!
Time of Update: 2021-04-19
Medical Network, March 29, March 26, the "Regular Policy Briefing of the State Council" explained the relevant situation of the "Regulations on the Supervision and Administration of Medical Devices"
-
The results of the fourth batch of national selection, six provinces have clarified the implementation time
Time of Update: 2021-04-19
46 ，6，20，427 6 45，、、、、、。 ，，20，。 ，10。，5，5，。 42，《》。 ，2021428，、，。 pharmnet. com. cn/news/yyzb/" target="_blank">、《》。 ，，3，，。 ，15，30%，。，，30。 330，《》，202151。 。，，。 、，3-5，。 ，50%。，。，。 326，《
-
The KHB-1802 project of Kanghong Pharmaceutical Conbercept ophthalmic injection is suspended in France
Time of Update: 2021-04-19
had recently received Agence nationale de sécurité du médicament et des produits de santé (French National Agency for the Safety of Medicines and Health Products, hereinafter referred to as ANSM) "A multi-center, double-blind, randomized, dose range trial to evaluate the efficacy and safety of Conbercept ophthalmic injection in the treatment of neovascular age-related macular degeneration" clinical trial project 2 ( KHB-1802) notice of suspension in France.
-
Tide Pharmaceuticals was commended by the National Chamber of Commerce and Industry of the Pharmaceutical Industry
Time of Update: 2021-04-19
has won two honors, the "Development Contribution Award" of the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce and the 2020 "Star Vice President Unit".
-
Bayer's pulmonary hypertension drug Adempas reaches its primary endpoint in Phase IV clinical trial
Time of Update: 2021-04-19
Compile Ke KeOn March 29, Bayer announced the publication of Phase IV clinical data of the pulmonary hypertension drug Adempas (riociguat) in The Lancet Respiratory Medicine.
This prospective, randomized, controlled, open-label study included 226 cases of pulmonary hypertension (PAH) The results of the patient (WHO Group 1) reached its primary endpoint.
-
Retail TOP20 of proprietary Chinese medicine plasters released!
Time of Update: 2021-04-19
2020E Key City Entity Pharmacy TCM Plaster Brand TOP20 Source: Mi Nei. com's terminal competition pattern of physical pharmacies in key cities In terms of brand TOP20, Tibet Qizheng Tibetan Medicine's Xiaotong Plaster, Yunnan Baiyao Wuxi Pharmaceutical's Yunnan Baiyao Cream, Anke Yuliangqing Pharmaceutical's Huoxuezhitong Ointment ranked in the top three, Henan Lingrui Pharmaceutical's Tongluo Qupain Five products including Zhuanggushexiang Pain Relief Cream and Joint Pain Relief Cream are among the TOP20 brands.
-
The National Health and Medical Commission's Medical Management Bureau issued the "Long-term Prescription Management Standards"
Time of Update: 2021-04-19
Chapter 5 Long-term prescription drug management Article 26 Primary medical and health institutions shall include the long-term prescription information issued by the institution in the patient's health file, and record the patient's diagnosis and treatment and medication records in detail.
-
Corning Jerry CMO, CFO confirmed
Time of Update: 2021-04-19
Johannes Nippgen, the former head of Merck’s China R&D Center, as the Chief Medical Officer (CMO), and Mr.
It is understood that before joining Corning Jerry, Johannes Nippgen served as the head of the China R&D center at Merck Biopharmaceuticals.
-
Detailed analysis of TOP20 global pharmaceutical companies by revenue in 2020!
Time of Update: 2021-04-19
The COVID-19 vaccine Comirnaty achieved $154 million in sales after receiving emergency approval in December last year.
S. dollars, and it is expected that COVID-19 vaccine sales this year will reach approximately 15 billion U.
-
Chinese biopharmaceuticals are trapped in a prisoner’s dilemma: the original innovative drugs have little investment and get together with innovative drugs
Time of Update: 2021-04-19
Therefore, the truly original and innovative drugs needed by patients and the market are in a prisoner's dilemma where no investment can be obtained.
-
8 major varieties, the implementation of centralized procurement results (list attached)
Time of Update: 2021-04-19
Centralized procurement expansion and contract renewal, competition between pharmaceutical companies continues The first round of 4+7 centralized procurement: 11 pilot cities, 25 varieties, a 12-month procurement cycle, the centralized procurement document was released on November 15, 2018, and the official results were released on December 7, 2018, and 2-3 in 2019 It will land in the next month, that is to say, by February-February 2020, the results of the first round of centralized procurement will be basically implemented.
-
K drug treatment of high-risk early triple-negative breast cancer encounters a complete response letter from the US FDA
Time of Update: 2021-04-19
The sBLA seeks to approve Keytruda for the treatment of high-risk early triple-negative breast cancer (TNBC) patients, specifically: Keytruda combined with chemotherapy for neoadjuvant (preoperative) treatment, and then Keytruda as a single drug for adjuvant (postoperative) treatment.
-
Fuhong Henlius plans to submit a listing application for phase 2 clinical trial of anti-PD-1 antibody reaching the primary endpoint
Time of Update: 2021-04-19
The primary endpoint reached this time is a single-arm, open, multiple-arm, open-ended, multiple-arm, open-ended, multiple-arm, unresectable or metastatic MSI-H or dMMR solid tumor patient who has failed standard treatments to evaluate the efficacy, safety, and tolerability of HLX10.
-
Jingfeng Medicine Tirofiban Hydrochloride and Sodium Chloride Injection Passed the Consistency Evaluation
Time of Update: 2021-04-19
Approval Notice", this product has passed the generic drug quality and efficacy consistency evaluationTirofiban Hydrochloride Sodium Chloride Injection is mainly used for adult patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) who have ECG changes and/or elevated myocardial enzymes within 12 hours of the last chest pain onset , To prevent early myocardial infarction.
-
Targeting Claudin 18.2 and 4-1BB!
Time of Update: 2021-04-19
2, TJ-CD4B can still bind to tumor cells and produce better immune activity than other 4-1BB monoclonal antibodies, making it expected to be suitable for a wider range of patients group.
-
Zheng Lei will serve as the new president of Xi'an Yangsen
Time of Update: 2021-04-19
On March 29, 2021, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, announced that from April 1, 2021, Ms.
Zheng Lei will serve as President of Xi'an Janssen Pharmaceuticals Co.
-
None of the five global top 10 generic drug companies in India are from China!
Time of Update: 2021-04-19
Allergan's generic drug business acquired by Teva was renamed through continuous mergers and acquisitions by Watson Pharmaceuticals, the third largest generic drug company in the United States.
-
Well-known pharmaceutical company announced the abolition of employees
Time of Update: 2021-04-19
Senior medical representative Joe said to Cyberland: The current response strategy of foreign companies to centralized procurement is to abolish and reduce the size of the team that may purchase products in the future, outsourcing products that are not well done, merging between mature products, and focusing on the layout of innovative drugs.
-
Tens of billions of funds to exert force!
Time of Update: 2021-04-19
Innovative products soar Significant acceleration in the introduction of authorization License-in, as a conventional new drug cooperation model, skips the long process of early internal development, quickly integrates external collaboration or complementary resources, and brings the company a product line that meets the overall strategic plan as soon as possible, and has achieved a number of license-in products.
